Carisbamate

Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy[1][2][3].

Product Specifications

CAS Number

[194085-75-1]

Product Name Alternative

RWJ-333369

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/carisbamate.html

Purity

98.75

Solubility

DMSO : ≥ 100 mg/mL

Smiles

NC(OC[C@H](C1=CC=CC=C1Cl)O)=O

Molecular Formula

C9H10ClNO3

Molecular Weight

215.64

Precautions

H302, H315, H319, H335

References & Citations

[1]Deshpande LS, et al. Carisbamate prevents the development and expression of spontaneous recurrent epileptiform discharges and is neuroprotective in cultured hippocampal neurons. Epilepsia. 2008 Oct;49 (10) :1795-802. |[2]François J, et al. Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia. 2008 Mar;49 (3) :393-9. |[3]Novak GP, et al. Carisbamate (RWJ-333369) . Neurotherapeutics. 2007 Jan;4 (1) :106-9.